|Bid||0.00 x 800|
|Ask||38.99 x 900|
|Day's Range||38.81 - 39.47|
|52 Week Range||34.37 - 46.47|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||20.89|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||1.44 (3.39%)|
|1y Target Est||44.36|
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Lilly and partner Pfizer Inc. (NYSE: PFE) said in a Thursday news release the Phase 3 study intended to evaluate tanezumab in 2.5mg and 5mg doses for its long-term safety and 16-week efficacy relative to nonsteroidal anti-inflammatory drugs, or NSAIDs, in patients with moderate-to-severe osteoarthritis of the hip or knee produced mixed results. Tanezumab is an investigational monoclonal antibody that selectively targets, binds and inhibits nerve growth factor, or NGF, which increases as a result of injury, inflammation or in chronic pain states.
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
What to Expect from Pfizer’s Q1 2019 Results(Continued from Prior Part)Financial performance in the first quarterWall Street analysts expect Pfizer’s (PFE) revenues to be $12.99 billion, $13.37 billion, $13.07 billion, and $13.63 billion,
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its
U.S. stock futures are trading lower as traders return from the Easter holiday weekend.Ahead of the bell, futures on the Dow Jones Industrial Average are down 0.39%, and S&P 500 futures are lower by 0.40%. Nasdaq-100 futures have shed 0.57%.In the options pits on Thursday, call volume led the charge, and overall volume levels ended slightly above average. Specifically, about 20.5 million calls and 17.9 million puts changed hands on the session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, those calls didn't translate over to the CBOE, where the single-session equity put/call volume ratio ramped to 0.62 -- a one-week high. Meanwhile, the 10-day moving average held steady at 0.60.Here are three popular stocks landing atop the most-active options list: Pfizer (NYSE:PFE), Canopy Growth Corp (NYSE:CGC) and Microsoft (NASDAQ:MSFT).Let's take a closer look: Pfizer (PFE)Weakness in the healthcare sector spilled into biopharma. Pfizer fell 6.4% over the final three trading sessions of the week to close at a new nine-month low. The groundswell in volume during Friday's swoon revealed panic was in the air and could help to spell a short-term low in the now deeply oversold stock.But with PFE submerged deeply beneath all major moving averages, expect any relief rally to be short-lived. * 10 Best Stocks to Buy and Hold Forever The next earnings release is slated for April 30.On the options trading front, puts ruled the roost. Activity jumped to 417% of the average daily volume, with 129,626 total contracts traded. Puts edged out calls to claim 53% of the day's take.The increased demand drove implied volatility higher on the day to 26%, placing it at the 60th percentile of its one-year range. Premiums are officially juiced and no price in daily moves of 65 cents or 1.7%. Canopy Growth Corp (CGC)Canopy Growth Corp shares saw heightened volatility on Thursday after the company reported a deal giving it the right to buy Acreage Holdings (OTCMKTS:ACRGF). Acreage Holdings operates in the U.S., and its purchase will allow CGC to expand into the country if the federal government ever decides to legalize cannabis.The initial surge on the news carried CGC stock up as much as 11.4%. However, by day's end, profit-taking pared the gain to 3.9%. For the past two months, Canopy Growth Corp shares have been locked in a trading range. Thursday's jump had the potential to finally break the stock out, but the substantial amount of selling that came in near resistance rejected the attempt. Until we see a proper breach of the ceiling at $47.50, CGC remains a tricky trade.On the options trading front, traders gobbled up call options. Total activity grew to 315% of the average daily volume, with 133,768 contracts traded; 71% of the trading came from call options alone.Implied volatility popped on the day to 56%, but remains near the lower end of its one-year range. Microsoft (MSFT)The technology sector has been a standout in recent months, and Microsoft is arguably the poster child for its strength. MSFT stock surged to a new record high on Thursday, bringing its year-to-date gains to 21.6%. The profits come as investors gear up for the software sultans next earnings release on April 24.The catalyst for Thursday's euphoria was Microsoft announcing its purchase of Express Logic.On the options trading front, calls outpaced puts by a wide margin. Activity climbed to 224% of the average daily volume, with 285,449 total contracts traded; 67% of the trading came from call options alone.Implied volatility remains at the low end of its range, which suggests investors have little fear heading into earnings. At 24%, implied volatility sits at the 20th percentile of its one-year range. Premiums are baking in daily moves of $1.85 or 1.5%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Monday's Vital Data: Pfizer, Canopy Growth Corp and Microsoft appeared first on InvestorPlace.
What to Expect from Pfizer’s Q1 2019 ResultsShare price movementsPfizer’s earnings results for the first quarter of 2019 are expected to be released on April 30. On April 18, Pfizer (PFE) and Eli Lilly and Company (LLY) issued a press release
The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday. The drug was approved in combination with Pfizer Inc's Inlyta to treat advanced renal cell carcinoma. The approval, which comes two months ahead of expectations, allows this combination therapy to get an early launch ahead of other rival products, Cowen analyst Yaron Werber said, after the company received FDA approval on Friday.
When Pfizer (NYSE:PFE) won its first approval for cancer drug Ibrance back in February 2015, as a treatment for ER+/HER2- breast cancer, investors were cautiously optimistic. PFE stock holders knew it worked well enough for a narrow subset of breast cancer patients, but expectations for the then-nascent therapy were clearly high.Source: Maciek Lulko (Modified)The drug hasn't disappointed. Since early 2015, Ibrance has been approved for three more indications, with the most recent one taking shape just this month. As it turns out, the treatment has proven effective as a therapy for some of the rare cases where men develop breast cancer.It's a testament to the drug's incredible versatility and efficacy.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yet, while Ibrance is still in trials looking for even more approved uses, the company's future hardly hinges on what's quickly turning into a blockbuster drug. The market is largely overlooking much of Pfizer's pipeline. Catalysts AheadBank of America Merrill Lynch analyst Jason Gerberry made the point of making the call three weeks ago, upping the brokerage firm's price target on PFE stock from $45 to $48 on upcoming catalysts related to the development of two orphan drugs.Orphan drugs, in short, take aim at underserved areas of the pharmaceutical market. In many cases there are so few cases of a particular illness that no pharmaceutical company bothers developing an option, so when one does, the FDA facilitates an easier path to approval; something is better than nothing.One such drug in Pfizer's pipeline is Vyndaqel.It's not a new drug. In fact, it was first approved back in 2011. Its potential use as a treatment for cardiomyopathy, however, is in the works, and is expected to launch later this year to a receptive caregiver environment.All told, BofA-ML's Gerberry sees peak sales of $2 billion for Vyndaqel.Gerberry also notes that a Pfizer gene therapy candidate -- PF-06939926 for Duchenne muscular dystrophy -- is closer to the endzone than many current and would-be owners of PFE stock may realize. Though in Phase 1 testing right now, should the R&D update slated for the middle of the year go as well as expected, the drugmaker may be able to leap straight to Phase 3 trials and catch up with a similar development from DMD rival Sarepta Therapeutics (NASDAQ:SRPT). * 7 High-Risk Stocks With Big Potential Rewards Again, it's not only another catalyst that could draw a bullish crowd, but it's also a development that could put real revenue growth on the table real soon. The Duchenne muscular dystrophy market could be worth more than $4 billion by 2023.Outside of Gerberry's discussion, Pfizer's Vizimpro was approved earlier this month in Europe as a first-line treatment of locally advanced or metastatic non-small cell lung cancer.Pfizer's still got its R&D, or at least its therapy-acquiring, chops. Heavy HittersThough PF-06939926 and Vyndaqel should prove to be solid bolt-on revenue and profit centers, there's still little doubt that Ibrance will be the company's heavy hitter -- and growth driver -- for the foreseeable future.As of the company's most recent quarterly report, 12-month revenue for the wonder drug reached $4.1 billion, up 32% from the trailing-12-month figure reported a year earlier. New approvals and expanded usage for previously approved indications both helped.The drug, though, has still only scratched the surface. Some analysts are calling for peak revenue of around $8 billion before Ibrance runs out of room to grow and is crimped by rival drugs.Again, that potential is a testament to the drug's flexibility.Ibrance isn't the only heavy-hitter still in growth mode in Pfizer's lineup though. While Enbrel (sold by Pfizer in Europe), Sutent and Celebrex may all be major names with declining revenue, sales of fibromyalgia treatment Lyrica appear to have stabilized around an annual pace of $4.6 billion. Ditto for pneumococcal bacteria treatment Prevnar, which has driven more than $5 billion in sales over the course of the past four reported quarters.In the meantime, Pfizer has started to shine in an area that had quietly gnawed at PFE stock owners… biosimilars. The company has sold $642 million worth of ulcerative colitis, arthritis and plaque psoriasis drug Inflectra/Remsima over the past year, up 50% year-over-year, and suggesting it doesn't have to yield to the pharmaceutical industry's biosimilar powerhouses like Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN). * 7 Stocks to Buy for Spring Season Growth Pfizer's got five biosimilar drugs in the works, positioning it for deeper penetration of an admittedly-crowded market forecasted to be worth more than a stunning $60 billion by 2024. Bottom Line for PFE StockPFE stock is down 15% from its November peak, never really rebounding with the rest of the market beginning in January. Shares are down 10% just since early April, as the future of U.S. health care has become blurred by political rhetoric. Indeed, Pfizer stock hasn't made net progress since the middle of last year. Clearly there's something wrong with the company.Or, maybe there isn't.Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full. Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize.That may not be enough to stave off headline-driven headwinds in the short run. But, there's a reason a streak of downgrades late last year has been countered this year with a couple of upgrades to an "Outperform'" rating.One of those upgrades came from Credit Suisse, with analyst Vamil Divan noting that patent woes working against aforementioned therapies like Enbrel and Celebrex are starting to abate at the same time new therapies are reaching their full stride.It's just a story not many investors are paying attention to right now.As of this writing, James Brumley did not hold a position in any of the aforementioned companies. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Pfizer Stock Suffers From an Underappreciated Drugs Pipeline appeared first on InvestorPlace.
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% after hours, following a 1.3% decline to close at $39.38 in the regular trading session. Lilly shares fell 1.9% after hours, following a 1.1% close lower at $115.20. The companies said that a late-stage study of their drug tanezumab at 5 mg did not show a statistically significant improvement in overall osteoarthritis symptoms compared with nonsteroidal anti-inflammatory drugs. A 2.5 mg dose did not show a statistically significant improvement in pain, physical function or patients' overall assessment, the companies said. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, Pfizer's tanezumab development team leader, in a statement. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."
A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.
About $150 billion of market value was erased from companies in the S&P 500 Health Care Index in the four days through Thursday, when markets closed for the holiday weekend. “This is third-worst that I’ve seen probably in the last 10 years,” Christian Fay, who helps manage $3.6 billion at BNP Paribas Asset Management, said in a telephone interview.
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs. Patients who received tanezumab 2.5 mg did not experience a statistically significant improvement in pain, physical function or patients’ overall assessment of their OA at 16 weeks compared to NSAIDs.
The retreat in healthcare stocks is bleeding over, with areas like pharmaceutical sector exchange traded funds being dragged down by association. The iShares U.S. Pharmaceuticals ETF (IHE) continued its downward spiral Thursday, falling 0.4%. “Clearly, huge stock impacts to HCA and managed care can’t be ignored and ‘collateral damage’ to sub-sectors like biopharma in the following days are reflective of a view that mutual funds are drawing down and souring” on health care, Jefferies analyst Michael Yee wrote in a note, according to Bloomberg.
Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.